Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Jung's paternity reveal exposes where Korea stands on extramarital babies

    Jung's paternity reveal exposes where Korea stands on extramarital babies
  2. 2

    Samsung entangled in legal risks amid calls for drastic reform

    Samsung entangled in legal risks amid calls for drastic reform
  3. 3

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul

    Heavy snow alerts issued in greater Seoul area, Gangwon Province; over 20 cm of snow seen in Seoul
  4. 4

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'

    [Herald Interview] 'Trump will use tariffs as first line of defense for American manufacturing'
  5. 5

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations

    Agency says Jung Woo-sung unsure on awards attendance after lovechild revelations
  1. 6

    [Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle

    [Health and care] Getting cancer young: Why cancer isn’t just an older person’s battle
  2. 7

    Seoul blanketed by heaviest Nov. snow, with more expected

    Seoul blanketed by heaviest Nov. snow, with more expected
  3. 8

    K-pop fandoms wield growing influence over industry decisions

    K-pop fandoms wield growing influence over industry decisions
  4. 9

    [Graphic News] International marriages on rise in Korea

    [Graphic News] International marriages on rise in Korea
  5. 10

    Korea's auto industry braces for Trump’s massive tariffs in Mexico

    Korea's auto industry braces for Trump’s massive tariffs in Mexico
소아쌤

Danaher rebrands GE Healthcare Life Sciences to Cytiva

By Lim Jeong-yeo

Published : April 2, 2020 - 16:52

    • Link copied

Danaher said Thursday it has launched Cytiva -- formerly GE Healthcare Life Sciences, which it acquired for $21.4 billion -- aiming to completely rebrand the biologics side of General Electric’s business.

Cytiva’s projects, spanning from cell and gene therapies to protein research, biosimilar and novel biologics drug development, are highly in demand amid the COVID-19, according to the Cytiva CEO and president, Emmanuel Ligner.

After the transition from GE Healthcare Life Sciences to Cytiva, the company will retain its existing staff of 7,000 across 40 nations.

In South Korea, Cytiva’s local office, headed by Hong Seong-yong, runs a biologics drug research and development training center in Songdo, Incheon.

By Lim Jeong-yeo (kaylalim@heraldcorp.com)

More from Headlines